SCHEMBL614189

SCHEMBL614189

CC1(C)NC(=O)c2sc(-c3cn[nH]c3)cc2N1CC(=O)N1CCOCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 7/20 0.57
CDC7 O00311 6/20 0.57
CCNE1 P24864 6/20 0.57
ROCK1 Q13464 6/20 0.57
DBF4 Q9UBU7 6/20 0.57
PRKCQ Q04759 1/20 0.40
HTT P42858 2/20 0.39
GSK3B P49841 1/20 0.38
PIK3CA P42336 2/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
HSD17B10 Q99714 1/20 0.36
PIK3R1 P27986 1/20 0.36
MTOR P42345 1/20 0.36
PTK6 Q13882 2/20 0.36
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10238496 0.81 CDC7 (0.62) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL612604 0.80 HTT (0.42) HTTNPC1MITFLMNARAB9A
SCHEMBL612142 0.74 CDC7 (1.00) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL613707 0.68 CDC7 (0.72) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL613725 0.67 CDC7 (0.71) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL614159 0.66 CDC7 (0.57) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL613553 0.66 CDC7 (0.70) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL613190 0.66 CDC7 (0.73) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL614685 0.65 CDC7 (0.69) CDK2CDC7CCNE1ROCK1DBF4
SCHEMBL30274193 0.65 CDK2 (0.58) CDK2CDC7CCNE1ROCK1DBF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8691828-B2 Thienopyrimidine as CDC7 kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-04-08 US disclosed
US-8691828-B2 Thienopyrimidine as CDC7 kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-04-08 US disclosed
EP-2403857-B1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-12-04 EP disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040981-A1 THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS CDC7, CDK7, DTYMK CDK2 41/4885CDC7 1/4885CCNE1 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.